Radionuclide-Labeled Antibody Imaging Agents for PD-L1 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting PD-L1 expression in cancer tissues are inaccurate due to heterogeneous expression, limited binding sites, and the need for clear definition of positive staining, which complicates the assessment of immune checkpoint ligand distribution and therapeutic response.
Innovation Solution
Development of anti-PD-L1 antibodies as imaging agents labeled with radionuclides for non-invasive imaging techniques, allowing for the determination of PD-L1 distribution and expression levels in individuals, enabling precise diagnosis and treatment targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunohistochemistry (IHC) is used to detect PD-L1 expression, then PD-L1 expression level can be assessed, but measurement precision is reduced due to heterogeneous expression, limited binding sites, and lack of clear positive staining definition
Solution Approach 1:
The patent replaces the mechanical IHC staining process with a non-invasive imaging system that uses imaging agents (such as PET or SPECT agents) to detect PD-L1 expression. This substitution eliminates the need for tissue sectioning, staining, and subjective visual assessment, thereby resolving the ambiguity in defining positive staining and improving measurement precision.
Solution Approach 2:
The patent changes the detection parameter from qualitative/semi-quantitative IHC staining intensity to quantitative imaging signal intensity. By using imaging agents that emit detectable signals (e.g., radioactive decay), the system transforms the measurement into an objective, quantifiable parameter that can be precisely measured and compared, eliminating the subjectivity inherent in IHC positive staining definition.
2Adaptability or versatility
If multiple PD-L1 antibodies are used for IHC detection, then detection coverage is improved, but device complexity increases and reliability remains uncertain due to lack of comparative performance data
Solution Approach 1:
The patent employs a single imaging agent that can universally detect PD-L1 expression without requiring multiple different antibodies or staining protocols. The imaging agent is designed to specifically bind to PD-L1 and produce a detectable signal, providing a unified detection method that works across different tissue types and expression levels, thereby maintaining versatility while reducing complexity.
3Stability of the object's composition
If IHC methods are used on FFPE specimens, then tissue preservation is maintained, but measurement precision decreases due to limited binding sites on PD-L1
Solution Approach 1:
The patent replaces the IHC mechanical staining system with a non-invasive imaging system that detects PD-L1 through signal emission from imaging agents. This substitution allows detection in preserved tissues (FFPE specimens) without relying on antibody binding to epitopes that may be damaged or masked during formalin fixation and paraffin embedding, thereby maintaining both tissue stability and measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides accurate and dynamic imaging of PD-L1 distribution, facilitating personalized cancer therapy by identifying PD-L1 expression levels and guiding therapeutic decisions.
Implementation Method 1
administering to the individual an imaging agent comprising an antibody moiety labeled with a radionuclide
Implementation Method 2
imaging the imaging agent in the individual with a non-invasive imaging technique
Data Source
AI summary
Provided are methods, imaging agents and kits for determination of the distribution and expression levels of an immune checkpoint ligand (such as PD-L1 or a PD-L1 like ligand) in an individual having a disease or condition. Anti-PD-L1 antibody agents are also provided.